A new weapon against the obesity
by Claire Gabillat
While acting on the brain, sibutramine accelerates satiety.
Less to eat all while being faster satisfied: all the persons that suffer from obesity - be between 7 and 8% of the French population - would like to reach there. A hope that could become reality thanks to the sibutramine. This new class of medicines has in fact the property to diminish the craving to eat, reducing the alimentary consumption. Already disponible in about thirty countries, she will be commercialised in France of here about ten days. To the price of 500 francs (for a treatment of a month). His originality holds especially to his action mode.
So far, in France, the only medicine allowing to treat the obesity to long term was orlistat, a molecule that acts on the mechanism of the digestion while preventing the absorption of a third of ingested greases. Sibutramine actes on the brain, increasing the satiety sensation. Satisfied faster, the patient eats less and loses superfluous kilos. «Sibutramine diminishes the alimentary hold of 20 to 30%, summarizes Ziegler Olivier, nutrition professor to the CHU of Nancy. What meanes, concretely, an average loss of 5 to 10% of the initial weight on a year. A durable result. This new molecule allows not only slim, but also to maintain the obtained weight reduction. Managed in an only daily dose, this medicine is't a miracle remedy. As the fact to notice Ziegler Pr, «his effectiveness is comparable to the one of all the used medicines at the present time in obesity».
In a third of cases, results are superior to the average, but, for another third of patients, the weights loss is inferior to what is awaited. Besides, his prescription cannot be dissociated of a losing of fresh program: hypocalorique nutrition, physical activity and change of behaviors. Of even, she is uniquely reserved to the obese persons or presenting an associated risk factors (diabetes, arterial hypertension, dyslipidemia), in failure position. At last, she is contra-indicated in hypertensives, coronarians and subjects suffering from cardiac disturbances or having antecedents of vascular accidents. If the sibutramine does not seem to induce pulmonary arterial hypertension, as did the dexfenfluramine, a cutting-hunger withdrawn today of the market, she is not nevertheless without secondary effects. She notably can provoke a light increase of arterial tension and cardiac frequency.